GO:0090038 negative regulation of protein kinase C signaling: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090038 describes any process that decreases the frequency, rate, or extent of signaling mediated by protein kinase C (PKC), a family of intracellular serine/threonine kinases.
• PKC signaling is negatively regulated at multiple levels, including diacylglycerol (DAG) availability, phosphorylation status, subcellular localization, and interaction with scaffold proteins.
• Diacylglycerol kinases (DGKs) are key negative regulators that terminate PKC signaling by converting DAG to phosphatidic acid.
• Dysregulation of negative regulation of PKC signaling contributes to cancer, immune disorders, and metabolic diseases.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of negative regulatory mechanisms in PKC signaling.
• Understanding GO:0090038 provides insights into therapeutic strategies targeting PKC pathways in diseases such as cancer and inflammation.
Description
Protein kinase C (PKC) is a family of serine/threonine kinases that transduce signals from diverse extracellular stimuli, including hormones, neurotransmitters, and growth factors. PKC signaling is tightly controlled to prevent aberrant activation, and negative regulation of this pathway is essential for normal cellular homeostasis. The Gene Ontology term GO:0090038, negative regulation of protein kinase C signaling, captures the processes that decrease the frequency, rate, or extent of PKC-mediated signaling. This term is critical for researchers studying signal transduction, as dysregulation of PKC negative regulation is implicated in cancer, immune dysfunction, and metabolic disorders. Mechanistically, negative regulation of PKC signaling can occur through multiple routes, including the action of diacylglycerol kinases (DGKs) that deplete the activating lipid second messenger DAG, phosphatases that reverse activating phosphorylations, and protein-protein interactions that sequester PKC away from its substrates. For example, DGK-mediated conversion of DAG to phosphatidic acid directly attenuates PKC recruitment and activation. Additionally, tyrosine phosphorylation of PKC isoforms can modulate their activity and downstream signaling in infection and inflammation. Given the broad impact of PKC signaling on cellular physiology, understanding its negative regulation is essential for developing targeted therapies. This article synthesizes current knowledge on GO:0090038, covering its definition, mechanisms, key genes, disease relevance, and research methodologies, with a focus on CRISPR-based approaches for functional validation.
negative regulation of protein kinase C signaling At A Glance
| GO ID | GO:0090038 |
|---|---|
| GO term | negative regulation of protein kinase C signaling |
| Ontology | biological_process |
| Synonym | negative regulation of protein kinase C signaling cascade; negative regulation of protein kinase C signalling cascade |
| Definition | Any process that decreases the frequency, rate, or extent of a series of reactions, mediated by the intracellular serine/threonine kinase protein kinase C, which occurs as a result of a single trigger reaction or compound. |
| Major function | Attenuation of PKC-mediated signal transduction to prevent aberrant cellular responses. |
| Related kinases | Protein kinase C isoforms (e.g., PKC-alpha, PKC-delta, PKC-theta), diacylglycerol kinases (DGKs). |
| Key regulators | Diacylglycerol kinases, protein phosphatases, scaffold proteins. |
| Disease relevance | Cancer, immune disorders, metabolic diseases, inflammation. |
What Is GO:0090038?
GO:0090038, negative regulation of protein kinase C signaling, is a biological process defined as any process that decreases the frequency, rate, or extent of a series of reactions mediated by the intracellular serine/threonine kinase protein kinase C, which occurs as a result of a single trigger reaction or compound. In simpler terms, it encompasses all molecular events that put the brakes on PKC signaling, ensuring that this kinase pathway is not overactive. This regulation can happen at the level of second messenger availability, kinase phosphorylation, localization, or interaction with regulatory proteins.
Why Is negative regulation of protein kinase C signaling Important in Cell Biology?
Negative regulation of protein kinase C signaling is crucial because PKC pathways control fundamental cellular processes such as proliferation, differentiation, apoptosis, and immune responses. Without proper negative regulation, sustained PKC activation can lead to oncogenesis, chronic inflammation, and metabolic dysfunction. For instance, PKC isoforms are implicated in radiation-induced apoptosis, where both positive and negative regulation determine cell fate. Moreover, conventional PKC plays a critical role in negative regulation of CD98-induced homotypic aggregation, highlighting its importance in immune cell adhesion. Thus, understanding GO:0090038 offers insights into disease mechanisms and potential therapeutic targets.
• Prevents aberrant PKC activation that can drive tumorigenesis and cancer progression.
• Modulates immune responses by regulating T-cell signaling and cytokine production.
• Controls platelet activation and thrombus formation through PKC isoform regulation.
• Influences metabolic homeostasis, including adipose tissue function and sex-dependent effects.
• Regulates apoptosis in response to radiation and other stress stimuli.
• Impacts inflammatory signaling pathways via tyrosine phosphorylation of PKC isoforms.
• Provides targets for therapeutic intervention in diseases with dysregulated PKC signaling.
• Essential for normal cellular differentiation and proliferation.
• Involved in negative regulation of cell adhesion processes, such as CD98-induced homotypic aggregation.
• Key for understanding signal transduction cross-talk with other pathways like interferon signaling.
What Happens During negative regulation of protein kinase C signaling?
Termination of Diacylglycerol (DAG) Signal
In simple terms: DAG is the 'on switch' for PKC; removing it turns PKC off.
Diacylglycerol (DAG) is a lipid second messenger that recruits and activates PKC. Negative regulation of PKC signaling often begins with the conversion of DAG to phosphatidic acid by diacylglycerol kinases (DGKs), thereby terminating the PKC activation signal. This enzymatic reaction reduces the available DAG pool and prevents sustained PKC membrane recruitment and activation.
Dephosphorylation of PKC
In simple terms: Phosphatases remove phosphate groups from PKC, turning it off.
PKC activity is regulated by phosphorylation at specific residues. Protein phosphatases can dephosphorylate PKC, leading to its inactivation and degradation. This negative regulation ensures that PKC signaling is transient and reversible. The balance between kinases and phosphatases determines the duration and intensity of PKC signaling.
Sequestration by Scaffold Proteins
In simple terms: Scaffold proteins hold PKC in place, preventing it from reaching its targets.
Scaffold proteins can bind to PKC and sequester it in specific subcellular compartments, thereby preventing it from interacting with downstream substrates. This spatial regulation is a key mechanism for negative regulation of PKC signaling. For example, proteins containing PDZ domains can anchor PKC and limit its access to signaling partners.
Modulation by Tyrosine Phosphorylation
In simple terms: Adding phosphate groups to tyrosine residues on PKC can change its activity.
Tyrosine phosphorylation of PKC isoforms, particularly PKC-delta, can modulate its function in infection and inflammation. This post-translational modification can either enhance or inhibit PKC signaling depending on the context, and represents a point of negative regulation. The interplay between serine/threonine and tyrosine phosphorylation fine-tunes PKC output.
Regulation by Protein Kinase D (PKD)
In simple terms: PKD can act as a brake on PKC signaling in certain tissues.
Protein kinase D (PKD) is a downstream target of PKC but can also feed back to negatively regulate PKC signaling. In adipose tissue, PKD regulates signaling networks with sex-dependent effects on metabolism, illustrating tissue-specific negative regulation. This feedback loop helps maintain metabolic homeostasis.
Key Genes Involved in GO:0090038 negative regulation of protein kinase C signaling
The following genes and proteins are key players in the negative regulation of protein kinase C signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DGK (e.g., DGKA, DGKZ) | Converts DAG to phosphatidic acid, terminating PKC activation | Key negative regulators; targets for cancer and immune studies |
| PRKCA | PKC-alpha isoform; subject to negative regulation | Implicated in cancer and apoptosis |
| PRKCD | PKC-delta isoform; modulated by tyrosine phosphorylation | Role in infection and inflammation |
| PRKCQ | PKC-theta isoform; involved in T-cell signaling | Interferon signaling and immune regulation |
| PRKCB | PKC-beta isoform; conventional PKC | Negative regulation of CD98-induced aggregation |
| PDPK1 | Phosphoinositide-dependent kinase-1; activates PKC | Upstream regulator; negative regulation via phosphatases |
| PTPN (protein tyrosine phosphatases) | Dephosphorylate PKC tyrosine residues | Modulate PKC activity in inflammation |
| PPP1CA | Protein phosphatase 1 catalytic subunit; dephosphorylates PKC | Negative regulation of PKC signaling |
| PPP2CA | Protein phosphatase 2A; dephosphorylates PKC | Tumor suppressor; negative regulation |
| PRKD1 | Protein kinase D1; downstream of PKC, feedback regulation | Adipose tissue metabolism |
| PRKD2 | Protein kinase D2; regulates PKC signaling | Metabolic and immune functions |
| RACK1 | Receptor for activated C kinase; scaffolds PKC | Modulates PKC localization and activity |
| AKAPs | A-kinase anchoring proteins; scaffold PKC | Spatial regulation of PKC |
| 14-3-3 proteins | Bind phosphorylated PKC and regulate localization | Negative regulation by sequestration |
| S100 proteins | Calcium-binding proteins; interact with PKC | Modulate PKC activity in cancer |
| HSP70 | Chaperone; regulates PKC stability | Protein quality control of PKC |
| CHP1 | Calcineurin homologous protein; regulates PKC | Ion transport and PKC signaling |
| PICK1 | PDZ domain protein; binds PKC-alpha | Sequesters PKC in neurons |
How Is negative regulation of protein kinase C signaling Regulated?
Negative regulation of PKC signaling is itself subject to regulation by various cellular inputs. For example, diacylglycerol kinases (DGKs) are regulated by phosphorylation, calcium, and lipid interactions, which control their ability to terminate DAG signaling. Protein phosphatases such as PP1 and PP2A are regulated by targeting subunits and inhibitors, influencing PKC dephosphorylation. Additionally, tyrosine phosphorylation of PKC-delta by Src family kinases can modulate its negative regulation in infection and inflammation. In adipose tissue, protein kinase D (PKD) is regulated by insulin and nutritional status, with sex-dependent effects on PKC signaling. These layers of regulation ensure that PKC signaling is appropriately attenuated in response to changing cellular conditions.
negative regulation of protein kinase C signaling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DGK | Cancer, immune disorders | DGK knockout cell lines; xenograft models |
| PRKCD | Infection, inflammation, cancer | PRKCD point mutant knock-in mice |
| PRKCQ | Autoimmune diseases, T-cell disorders | PRKCQ knockout T cells |
| PRKD1 | Metabolic syndrome, obesity | Adipose-specific PRKD1 knockout mice |
| PRKCB | Immune cell adhesion disorders | PRKCB knockout immune cells |
Cancer
Dysregulation of negative regulation of PKC signaling is frequently observed in cancer. Loss of DGK function can lead to sustained PKC activation, promoting tumor cell proliferation and survival. Conversely, PKC isoforms can act as tumor suppressors or oncogenes depending on context, and their negative regulation is critical for preventing oncogenesis. For example, PKC-delta tyrosine phosphorylation is altered in various cancers, affecting apoptosis and inflammation.
Immune and Inflammatory Disorders
PKC-theta is essential for T-cell activation, and its negative regulation prevents excessive immune responses. Defects in negative regulation can contribute to autoimmune diseases and chronic inflammation. Additionally, conventional PKC negatively regulates CD98-induced homotypic aggregation, and disruption of this process may lead to immune cell adhesion abnormalities. Tyrosine phosphorylation of PKC-delta also plays a role in infection and inflammation.
Metabolic Diseases
Protein kinase D (PKD) in adipose tissue regulates signaling networks with sex-dependent effects on metabolism. Impaired negative regulation of PKC signaling in adipose tissue may contribute to insulin resistance and obesity. Understanding these mechanisms could lead to sex-specific therapeutic strategies for metabolic disorders.
Cardiovascular Disease
PKC isoforms are critical for platelet activation and thrombus formation. Negative regulation of PKC signaling in platelets is necessary to prevent excessive thrombosis. Dysregulation can lead to bleeding disorders or pathological clot formation.
From negative regulation of protein kinase C signaling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does DGK negatively regulate PKC signaling in cancer cells? | DGK knockout cell lines (e.g., CRISPR-Cas9) |
| How does PKC-delta tyrosine phosphorylation affect inflammation? | PRKCD point mutation knock-in mice |
| What is the role of PKC-theta in T-cell interferon signaling? | PRKCQ knockout or knock-in T cells |
| Does PKD feedback regulate PKC in adipose tissue? | Adipose-specific PRKD1/2 knockout mice |
| How does PKC-beta regulate CD98-induced aggregation? | PRKCB overexpression or knockout in immune cells |
| What is the impact of PKC isoforms on platelet function? | Platelet-specific PKC knockout mice |
How to Study the negative regulation of protein kinase C signaling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on PKC signaling | Identify negative regulators |
| Phosphoproteomics | Global phosphorylation changes | Map PKC substrate networks |
| FRET biosensors | Real-time PKC activity | Live-cell signaling dynamics |
| RNA-seq | Transcriptional changes | Downstream gene expression |
| Western blot | Protein expression and phosphorylation | Validate specific targets |
| Immunoprecipitation | Protein-protein interactions | Identify PKC complexes |
| Flow cytometry | Cell phenotype and aggregation | Immune cell adhesion assays |
| Platelet aggregometry | Platelet activation | Thrombus formation studies |
CRISPR-Cas9 Knockout Screening
CRISPR-Cas9 knockout screens can identify genes whose loss enhances or suppresses PKC signaling. By targeting candidate negative regulators such as DGKs or phosphatases, researchers can assess their impact on PKC activity and downstream phenotypes. Pooled sgRNA libraries coupled with phospho-PKC readouts enable high-throughput discovery.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics allows global profiling of phosphorylation events regulated by PKC and its negative regulators. This method can reveal site-specific changes in PKC substrates and feedback loops. Quantitative phosphoproteomics is particularly useful for studying tyrosine phosphorylation of PKC isoforms.
Live-Cell Imaging
Genetically encoded FRET biosensors for PKC activity enable real-time visualization of signaling dynamics in living cells. These sensors can be used to study how negative regulators affect the amplitude and duration of PKC signals. Imaging can also track PKC translocation to membranes.
RNA Sequencing (RNA-seq)
RNA-seq can identify transcriptional changes resulting from altered negative regulation of PKC signaling. Comparing wild-type and knockout cells reveals downstream gene expression programs controlled by PKC. This approach is valuable for understanding long-term cellular responses.
How CRISPR Can Be Used to Study GO:0090038 negative regulation of protein kinase C signaling
Knockout
CRISPR-Cas9 knockout of negative regulators such as DGK or phosphatases can lead to enhanced PKC signaling, providing a direct test of their function. For example, DGK knockout cells show increased DAG levels and sustained PKC activation. Knockout models are essential for validating loss-of-function phenotypes in disease contexts.
Point Mutation
Point mutations can be introduced to mimic or abolish phosphorylation sites on PKC isoforms or their regulators. For instance, mutating tyrosine residues on PKC-delta can reveal their role in negative regulation during inflammation. CRISPR prime editing or homology-directed repair enables precise nucleotide changes.
Knock-in
Knock-in of tagged or reporter versions of PKC or its regulators allows for tracking protein localization and interactions. Fluorescent knock-in of PKC isoforms can be used to study real-time signaling dynamics. Knock-in of disease-associated mutations can model human disorders.
Overexpression
Overexpression of negative regulators such as DGK or phosphatases can suppress PKC signaling, confirming their inhibitory role. CRISPR activation (CRISPRa) enables targeted overexpression without exogenous constructs. This approach is useful for gain-of-function studies in cancer and immune cells.
How EDITGENE Supports negative regulation of protein kinase C signaling Research
Researchers studying negative regulation of protein kinase C signaling-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with its activity. EDITGENE provides comprehensive CRISPR-based services to enable precise functional interrogation of these genes in relevant cell models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of protein kinase C signaling research.
Frequently Asked Questions About negative regulation of protein kinase C signaling
What is negative regulation of protein kinase C signaling?
It is a biological process (GO:0090038) that decreases the frequency, rate, or extent of signaling mediated by protein kinase C, a serine/threonine kinase.
What genes are involved in negative regulation of protein kinase C signaling?
Key genes include diacylglycerol kinases (DGKs), protein phosphatases (e.g., PPP1CA, PPP2CA), and PKC isoforms themselves (e.g., PRKCD, PRKCQ).
How do diacylglycerol kinases regulate PKC signaling?
DGKs convert diacylglycerol (DAG) to phosphatidic acid, thereby removing the lipid second messenger required for PKC activation.
What diseases are associated with dysregulated negative regulation of PKC signaling?
Cancer, immune disorders, metabolic diseases, and cardiovascular diseases such as thrombosis.
What research methods are used to study negative regulation of PKC signaling?
CRISPR knockout screens, phosphoproteomics, FRET biosensors, RNA-seq, and Western blotting are commonly used.
How can CRISPR be used to study negative regulation of PKC signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes involved in the pathway.
What is the role of protein kinase D in PKC signaling?
Protein kinase D can act downstream of PKC and provide feedback negative regulation, with sex-dependent effects on metabolism.
How does tyrosine phosphorylation affect PKC-delta?
Tyrosine phosphorylation of PKC-delta modulates its activity in infection and inflammation, contributing to negative regulation.
Which PKC isoforms are involved in platelet function?
Multiple PKC isoforms regulate platelet activation and thrombus formation, and their negative regulation prevents excessive clotting.
What is the clinical relevance of PKC-theta in T-cells?
PKC-theta is critical for T-cell interferon signaling, and its negative regulation is important for preventing autoimmune responses.
Conclusion
GO:0090038, negative regulation of protein kinase C signaling, encompasses diverse molecular mechanisms that attenuate PKC pathway activity, including DAG depletion by DGKs, dephosphorylation by phosphatases, and sequestration by scaffold proteins. Dysregulation of these processes contributes to cancer, immune disorders, and metabolic diseases, making them attractive therapeutic targets. Advances in CRISPR-based models and high-throughput screening are accelerating the discovery of novel negative regulators and their roles in health and disease. EDITGENE provides end-to-end CRISPR services, from knockout and point mutation models to library screening and bioinformatics, empowering researchers to dissect the negative regulation of PKC signaling with precision and reproducibility.
References
- 1. Mérida I et al.. 2019. Diacylglycerol kinase control of protein kinase C.. Biochem J 476(8):1205-1219 PMID: 31000624
- 2. Nakajima T. 2008. Positive and negative regulation of radiation-induced apoptosis by protein kinase C.. J Radiat Res 49(1):1-8 PMID: 17785935
- 3. Renton MC et al.. 2025. Adipose tissue protein kinase D: regulation of signaling networks and its sex-dependent effects on metabolism.. Am J Physiol Endocrinol Metab 329(1):E67-E85 PMID: 40454664
- 4. Srivastava KK et al.. 2004. Engagement of protein kinase C-theta in interferon signaling in T-cells.. J Biol Chem 279(29):29911-20 PMID: 15150272
- 5. Cho JY et al.. 2010. Conventional protein kinase C plays a critical role in negative regulation of CD98-induced homotypic aggregation.. Tissue Antigens 75(1):19-29 PMID: 19895572
- 6. Yang Q et al.. 2019. The Role of Tyrosine Phosphorylation of Protein Kinase C Delta in Infection and Inflammation.. Int J Mol Sci 20(6) PMID: 30917487
- 7. Spitaler M et al.. 2004. Protein kinase C and beyond.. Nat Immunol 5(8):785-90 PMID: 15282562
- 8. Harper MT et al.. 2010. Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation.. J Thromb Haemost 8(3):454-62 PMID: 20002545
